Stock Taper 
Kura Oncology, a San Diego-based clinical-stage biopharmaceutical company, develops cancer treatments, including menin inhibitor ziftomenib and farnesyl transferase inhibitor tipifarnib, with ongoing clinical trials and collaborations like Novartis.
Komzifti (ziftomenib) is an FDA-approved, oral, selective menin inhibitor for relapsed/refractory NPM1-mutant AML, marking Kura Oncology's transition to a commercial-stage company with its leading therapeutic product.
The U.S. Food and Drug Administration (FDA) granted full approval to Kura Oncology's KOMZIFTI™ (ziftomenib) on November 13, 2025, for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation. This pivotal event marked the company's transition from a clinical-stage to a commercial-stage biopharmaceutical company and represented the first FDA-approved, once-daily oral menin inhibitor for this specific, genetically defined patient population. The approval triggered significant milestone payments and spurred widespread analyst upgrades.
In a pivotal strategic shift, Kura Oncology received FDA approval for its lead drug, KOMZIFTI™ (ziftomenib), in November 2025 and subsequently launched it for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible NPM1 mutation. This marks the company's transition from a clinical-stage to a commercial-stage biopharmaceutical company, a fundamental change in its operations and market position.
– Webcast scheduled for October 13, 2026, at 4:30 p.m. ET / 1:30 p.m. PT – – Webcast scheduled for October 13, 2026, at 4:30 p.m. ET / 1:30 p.m. PT –
SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on October 1, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 128,250 shares of common stock to nine (9) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Overall rating: C
| PEER | PRICE | |
|---|---|---|
 TNGX | $21.53 | COMPARE |
 HCM | $13.67 | COMPARE |
 NRIX | $22.22 | COMPARE |
 SLS | $11.13 | COMPARE |
 SNDX | $16.99 | COMPARE |
 ORIC | $11.82 | COMPARE |
 TYRA | $19.98 | COMPARE |
 MRVI | $8.13 | COMPARE |
